Plosaracetam (INNTooltip International Nonproprietary Name; developmental code names ABBV-552, SDI-118) is a synaptic vesicle glycoprotein 2A (SV2A) ligand which is under development for the treatment of Alzheimer's disease and other cognition disorders.[1][3][4][2] In contrast to earlier SV2A ligands like levetiracetam and brivaracetam, polsaracetam does not have anticonvulsant activity and instead shows pro-cognitive effects.[2] The drug is being developed by UCB Biopharma and AbbVie.[1][3] As of October 2024, it is in phase 2 clinical trials for Alzheimer's disease and phase 1 trials for cognition disorders.[1][3]

References

  1. ^ a b c d "ABBV 552". AdisInsight. 28 October 2024. Retrieved 26 February 2025.
  2. ^ a b c Botermans W, Koole M, Van Laere K, Savidge JR, Kemp JA, Sunaert S, et al. (2022). "SDI-118, a novel procognitive SV2A modulator: First-in-human randomized controlled trial including PET/fMRI assessment of target engagement". Frontiers in Pharmacology. 13: 1066447. doi:10.3389/fphar.2022.1066447. PMC 9887116. PMID 36733374.
  3. ^ a b c "Delving into the Latest Updates on Plosaracetam with Synapse". Synapse. 22 February 2025. Retrieved 26 February 2025.
  4. ^ "ABBV-552". ALZFORUM. 28 February 2023. Retrieved 26 February 2025.
Allikas: https://en.wikipedia.org/wiki/Plosaracetam
No tags for this post.